ALDH1A1 Expression in Invasive Mammary Carcinoma
- Conditions
- Breast Cancer
- Registration Number
- NCT06134570
- Lead Sponsor
- Sohag University
- Brief Summary
ALDH1A1 isozyme oxidizes Retinaldehyde to retinoic acid, which regulates the expression of the genes involved in tumor-initiating stem-like cells, thereby initiating tumor growth and resistance to drugs.
Much emphasis has been focused on ALDH1A1 as a CSC marker. High expression of ALDH1A1 has been reported as a poor prognostic marker in several tumor types and is associated with poor patient outcomes .
- Detailed Description
Breast cancer is one of the most common cancers among women. it is a heterogenous disease. several factors affect the prognosis of breast cancer. CSCs markers are one of the emerging prognostic biomarkers.
ALDH1A1 isozyme oxidizes Retinaldehyde to retinoic acid, which regulates the expression of the genes involved in tumor-initiating stem-like cells, thereby initiating tumor growth and resistance to drugs.
Much emphasis has been focused on ALDH1A1 as a CSC marker. High expression of ALDH1A1 has been reported as a poor prognostic marker in several tumor types and is associated with poor patient outcomes .
Recruitment & Eligibility
- Status
- ENROLLING_BY_INVITATION
- Sex
- Female
- Target Recruitment
- 60
- Patients with invasive mammary carcinoma carcinoma and underwent surgery
- Cases received pre-operative chemotherapy or radiotherapy.
- Cases with insufficient clinical data.
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method evaluate expression of ALDH1A1 in invasive mammary carcinoma 4 month immunohistochemical study
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Faculty of Medicine
🇪🇬Sohag, Egypt